byMediaBoost

Solstice Oncology

Raised $225M in a Series A round, announced 9 September 2026.

Round

Solstice Oncology launched with a $225 million Series A to advance porustobart in neoadjuvant cancer indications.

Amount
$225M
Stage
Series A
Announced
9 September 2026
Lead
RA Capital Management
Other investors
Canaan Partners, Forbion
Checked
Announced by the company

Company

Develops immunotherapies for earlier treatment of cancer

Based in
United States
Sector
Health
Website
solsticeoncology.com ↗

Founder

  • Caroline LoewCEO

Sources and links

Source
Harbour BioMed Partner, Solstice Oncology, announces $225 Million Series A Financing to Advance Porustobart, a prnewswire.com
Website
solsticeoncology.com ↗
MediaBoost

Just raised?

MediaBoost gets your round in front of the press, future hires and your next investors.

Announce your round with MediaBoost